Mark Cannon, M.D., Ph.D. Assistant Professor Department of Medicine Johns Hopkins School of Medicine, M.D. 1993 University College, London, Ph.D. 2007 canno101@umn.edu 612-624-8048 office 612-626-2527 lab

Research Interests:

Viral Tumorigenesis

The Cannon lab studies how Kaposi’s sarcoma-associated herpesvirus (KSHV) causes Kaposi’s sarcoma (KS) and other hyperproliferative diseases. KS is among the most common AIDS-related tumors and is the most common cancer in large parts of Africa. Our focus is the KSHV encoded chemokine receptor (vGPCR). vGPCR has the ability to affect several aspects of KS development including cell proliferation, angiogenesis, and the inflammatory component associated with early KS lesions. vGPCR does this through its broad and constitutive signaling.  Our goal is to identify how vGPCR deregulates normal host cell signaling pathways and to target them as part of an anti-vGPCR and ultimately an anti-KSHV therapeutic approach. In collaboration with the Bohjanen lab we are also investigating the effects of vGPCR signaling on mRNA stability. Our lab also has an interest in developing viral gene therapy vectors to specifically target KSHV- and EBV-mediated malignancies.

Selected Recent Publications:

• Bottero, V. ,Sharma-Walia, N., Kerur, N., Paul, A., Sadagopan, S., Cannon, M., Chandran, B. 2009. Kaposi Sarcoma-associated herpes virus (KSHV) G protein-coupled receptor (vGPCR) activates the ORF50 lytic switch promoter: A potential positive feedback loop for sustained ORF50 gene expression. Virology, in press

• Daniel Di Bartolo, Mark Cannon, Yi-Fang Liu, Rolf Renne, Amy Chadburn, Chris Boshoff, and Ethel Cesarman. 2008. KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood  111(9): 4731-40.

• Cannon, M. 2007. The KSHV and other human herpesviral G protein-coupled receptors. Current Topics in Microbiology and Immunology. 312, 137-156.

• Richard J. Vart, Leonid L. Nikitenko, Dimitrios Lagos, Matthew W. B. Trotter, Mark Cannon, Dimitra Bourboulia, Fiona Gratrix, Yasuhiro Takeuchi, Chris Boshoff.  2007. Kaposi’s Sarcoma-associated Herpesvirus encoded IL6 and GPCR Regulate Angiopoietin-2 Expression in Lymphatic Endothelial Cells. Cancer Research 67(9):4042-51.

• Cannon, M., Cesarman, E., Boshoff, C. 2006. The KSHV G protein-coupled receptor inhibits lytic gene transcription in primary effusion lymphoma cells via a p21-mediated inhibition of Cdk2.  Blood 107(1), 277-284.
  
  
• Cannon, M. & Cesarman, E. 2004. The KSHV G protein-coupled receptor signals via multiple pathways to induce transcription factor activation in primary effusion lymphoma cells. Oncogene 23(2), 514-523.

• Tyson V. Sharp, Fernando Munoz, Dimitra Bourboulia, Nadege Presneau, Eva Darai, Hsei-Wei Wang, Mark Cannon, David N. Butcher, Andrew G. Nicholson, George Klein, Stephan Imreh, and Chris Boshoff.  2004.   LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription PNAS 101, 16531-16536.

• Cannon, M., Philpott, N. J. & Cesarman, E. 2003. The Kaposi's Sarcoma-Associated Herpesvirus G Protein-Coupled Receptor Has Broad Signaling Effects in Primary Effusion Lymphoma Cells. J Virol 77:57-67.

• Cannon M, Cesarman E. 2000. Kaposi’s Sarcoma-Associated Herpes Virus and Acquired Immunodeficiency Syndrome-Related Malignancy. Seminars in Oncology 27(4), 409-419.
  
  
  

Last modified on: August 11, 2009